Metagenomi Therapeutics, Inc. (MGX): Cash & Equivalents
$41.72M
As of 2025-12-31
$39.03M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.72M | +52.3% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $27.39M | -80.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $140.60M | n/a | 2025-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| Alector, Inc. (ALEC) | 2025-12-31 | $65.80M | +99.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $25.18M | +24.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗